CONSORT-DEFINE解释和阐述:关于提升早期剂量检测临床试验报告质量和影响的建议
Jan Rekowski1, Christina Guo2,3, Olga Solovyeva1
1Clinical Trials and Statistics Unit at the Institute of Cancer Research, London, UK.
EClinicalMedicine
|January 29, 2025
概括
改善早期阶段剂量检测 (EPDF) 试验报告对于新疗法开发至关重要. CONSORT-DEFINE声明及其解释和阐述文件提高了EPDF试验报告的质量和透明度.
科学领域:
- 临床试验方法论 临床试验方法论
- 药物开发 药物开发
- 科学报告标准 科学报告标准
背景情况:
- 早期阶段剂量检测 (EPDF) 试验对于新疗法开发至关重要,指导随后的临床阶段,并告知反向翻译.
- 关于EPDF试验设计和结果的不完整和可变报告妨碍了准确的解释,并可能减缓治疗进展.
- 随机试验的CONSORT声明已经扩展到专门针对EPDF试验报告.
研究的目的:
- 介绍和解释CONSORT-DEFINE (报告试验剂量检测扩展的综合标准) 声明.
- 为CONSORT-DEFINE中的21个新的和19个修改后的检查列表项目提供详细的解释,理由和示例.
- 提高对CONSORT-DEFINE检查清单的理解并促进其实施,以改善EPDF试验报告.
主要方法:
- 通过基于国际共识的过程,制定CONSORT-DEFINE声明.
- 创建一个解释和阐述 (E&E) 文件,详细说明每个检查列表项目.
- 包括支持证据和来自EPDF发表的试验报告的例子.
主要成果:
- "CONSORT-DEFINE"声明包括21个新项目和对19个现有的CONSORT项目进行修改.
- 这份E&E文件为实施CONSORT-DEFINE检查清单提供了全面的指导.
- 来自同行评审文献的例子说明了检查列表项的应用.
结论:
- 预计CONSORT-DEFINE声明的广泛采用将大大提高EPDF试验报告的质量和透明度.
- 改进的报告将促进更准确的同行评审和研究人员,监管机构和资助者对EPDF试验的批判性评估.
- 坚持CONSORT-DEFINE的建议最终将加速新疗法的开发.
相关概念视频
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
115
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
115
Hazard Ratio
79
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
79


